Praxis Sets $20B+ Peak Sales Target, Discloses Launch Pricing and Two PDUFA Dates
PRAX has more than doubled off its 52-week low of $160.11.
Summary
Praxis used its Investor Day to disclose launch pricing for its two lead drugs and guide to more than $20B in combined peak sales, with FDA decisions on relutrigine (Dec 27, 2026) and ulixacaltamide (Jan 29, 2027) now weeks away.
Key Events · Product Development and Regulatory · PRAX
-
Investor Day Lays Out $20B+ Peak Sales
Management guided to more than $20B in combined peak sales: ulixacaltamide $10.0B, relutrigine $5.0B, vormatrigine $4.0B and elsunersen $1.0B.
-
Launch Pricing Corridors Disclosed
Ulixacaltamide is planned at $50K-$100K WAC per year in essential tremor and relutrigine at $400K-$600K WAC per year in SCN2A/SCN8A DEEs, benchmarked to in-market analogs.
-
Two PDUFA Dates Weeks Away
Relutrigine has a PDUFA date of December 27, 2026 and ulixacaltamide January 29, 2027; both launches are planned with field teams already hired and supply secured.
-
FDA Sensitivity Analyses Consistent
Sensitivity analyses of the Essential3 primary endpoint requested by FDA during NDA review were consistent with the primary result, including a baseline-observation-carried-forward analysis at 1.41 points (p=0.0019).
Analysis · PRAX · Life Sciences
At its Investor Day, Praxis put hard numbers on the commercial story for the first time: ulixacaltamide priced at $50K-$100K WAC per year in essential tremor and relutrigine at $400K-$600K per year in SCN2A/SCN8A DEEs, with combined peak sales guidance above $20B. Two near-term FDA decisions anchor the thesis — relutrigine on December 27, 2026 and ulixacaltamide on January 29, 2027 — so the next six weeks carry binary approval risk. The company also disclosed that FDA-requested sensitivity analyses of the Essential3 primary endpoint were consistent with the primary result, which removes a key review overhang. Against a $9.1B market cap, the guidance implies substantial upside if both labels clear, but the stock now trades on execution of two launches rather than pipeline optionality.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRAX was trading at $324.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.1B. The 52-week trading range was $160.11 to $392.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.